论文部分内容阅读
近日,欧洲药物管理局(E-MA)人用医药产品委员会(CHMP)发布积极意见,推荐批准扩大zykadia的适用人群,用于间变性淋巴瘤激酶阳性(ALK+)的晚期非小细胞肺癌(NSCLC)患者的一线治疗。如果获批,zykadia将为既往未接受治疗(初治)和新确诊为ALK阳性晚期NSCLC患者提供一个重要的一线治疗选择。zykadia是—一种口服、选择性间变性淋巴瘤激酶(ALK)抑制剂。对表达eml4-ALK、npm-ALK融
Recently, the European Medicines Agency (E-MA) Committee on Pharmaceutical Products for Human Use (CHMP) issued a positive opinion recommending the approval of an expanded population of zykadia for advanced non-small cell lung cancer (ALK +) with advanced non-small cell lung cancer (NSCLC First-line treatment of patients. If approved, zykadia will provide an important first-line treatment option for previously untreated (untreated) and newly diagnosed patients with ALK-positive advanced NSCLC. Zykadia is an oral, selective, anaplastic lymphoma kinase (ALK) inhibitor. For expression of eml4-ALK, npm-ALK fusion